Biomarker ST2 in cardiovascular pathology

O.V. Petyunina, M.P. Kopytsya, I.R. Vyshnevska

Key words: ST2, pathophysiology, diagnosis and prognosis of adverce outcome.

Published: 15.05.2018

References:

• Abela M.A. (2014) Biomarker guided approach in heart failure. Malta Med. J., 26(3): 46–51.
• Anand I.S., Rector T.S., Kuskowski M. et al. (2014) Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Cirk. Heart Fail., 7: 418–426.
• Bayes-Genis A., Zamora E., de Antonio M. et al. (2013) Soluble ST2 serum concentration and renal function in heart failure. J. Card. Fail., 19: 768–775.
• Boisot S., Beede J., Isakson S. et al. (2008) Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J. Card. Fail., 14: 732–738.
• Ciccone M.M., Cortese F., Gesualdo M. et al. (2013) A novel cardiac bio-marker: ST2: a review. Molecules, 18(12): 15314–15328.
• Coglianese E.E., Larson M.G., Vasan R.S. et al. (2012) Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham heart study. Clin. Chem., 58: 1673–1681.
• Demyanets S., Speidl V.S., Tentzeris I. et al. (2014) Soluble ST2 and Interleukin-33 in coronary artery disease: relation to disease activity and adverse outcome. Plos One, 9(4): e95055.
• Dieplenger B., Egger M., Haltmayer M. et al. (2014) Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen Risk and cardiovascular health study. Clin. Chem., 60: 530–554.
• Dieplenger B., Egger M., Poelz W. et al. (2011) Soluble ST2 is not independently associated with androgen and estragen status in healthy males and females. Clin. Chem. Lab. Med., 49: 1515–1518.
• Dieplenger B., Mueller T. (2015) Soluble ST2 in heart failure. Clin. Chim. Acta., 443: 57–70.
• Dhillon O.S., Narayan H.K., Quinn P.A. et al. (2011) Interleukin 33 and ST2 in non-ST elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am. Hear J., 161: 1163–1170.
• Dupuy A.M., Curinier C., Kuster N. et al. (2016) Multi-marker strategy in heart failure: combination of ST2 and CRP predicts poor outcome. Plos One, 11(6): E0157159.
• Eggers K.M., Armstrong P.W., Califf R.M. et al. (2010) ST2 and mortality in non-ST elevation acute coronary syndrome. Am. Heart J., 159(5): 788–794.
• Grabowski M., Szymanski F.M., Januzzi J. et al. (2009) Prognostic utility of serial measurements of a novel biomarker ST2 in STEMI patients treated by primary PCI. American Heart Association: scientific sessions. Circulation, 120: S808.
• Janussi J.L., Peacock F., Maisel A. et al. (2007) Measurement of the interleukin family member ST2 in patients with acute dyspnea. J. Am. Coll. Cardiol., 50: 607–613.
• Kohli P., Bonaca M.P., Kakkar R. et al. (2012) Role of ST2 in non-ST-elevation acute coronary syndrome in the MERILIN-TIMI 36 trial. Clin. Chem., 58(1): 257–266.
• Ky B., French B., McCloskey K. et al. (2011) High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ. Heart Fail., 4: 180–187.
• Lupón J., de Antonio M., Vila J. et al. (2014) Development of a novel heart failure risk tool: the Barcelona bio-heart failure risk calculator (BCN Bio-HF Calculator). PloS One, 9: e85466.
• Lupu S., Agoston-Codea L. (2014) Soluble ST2 in ventricular dysfunction. Adv. Clin. Chem., 69: 139–159.
• Maisel A., Richards A.M., Pasqual-Figal D. et al. (2015) Serial ST2 testing in hospitalized patients with acute heart failure. Am. J. Cardiol., 115: 32B–37B.
• Rehman S.U., Mueller T., Januzzi J.L. et al. (2008) Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol., 52: 1458–1465.
• Sabatini M.S., Morrow D.A., Higgins L.J. et al. (2008) Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type Natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation, 117: 1936–1944.
• Shan K.S., Maisel A. (2014) Novel biomarkers in heart failure with preserved ejection fraction. Heart Failure Clin., 10: 471–479.
• Shimpo M., Morrow D.A., Weinsberg E.O. et al. (2004) Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation, 109: 2186–2190.
• Socrates T., deFilippi C., Reichlin T. et al. (2010) Interleukin family member ST2 and mortality in acute dyspnoea. J. Intern. Med., 268(5): 493–500.
• Tung Y.-C., Chu P.-H. (2014) Soluble ST2: a novel prognostic biomarker of heart failure. Acta Cardiol. Sin., 30: 501–503.
• Wang T.J., Wollert K.S., Larson M.G. et al. (2012) Prognostic utility of novel biomarkers of cardiovascular stress. The Framingham Heart Study. Circulation, 126: 1596–1604.
• Wang Y.C., Yu C.C., Chiu F.C. et al. (2013) Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J. Card. Fail., 19: 163–168.
• Weinberg E.O., Shimpo M., De Keulenaer G.W. et al. (2002) Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction. Circulation, 106(23): 2961–2966.
• Weir R.A.P, Miller A.M., Murphy G.E.J. et al. (2010) Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. Am. Coll. Cardiol., 55: 243–250.